Company: CDLX
Filing Date: 2025-04-03
Form Type: ARS
Source: 0001666071-25-000048
Chunk: 103

Company: Cardlytics, Inc.
Filing Date: 2025-04-03
Form: ARS
Chunk 103
---
195 968 (8,932) Loss before income taxes (189,304) (134,702) (466,710) Income tax benefit — — 1,446 Net Loss (189,304) (134,702) (465,264) Net loss per share, basic and diluted $ (3.91) $ (3.69) $ (13.92) Weighted-average common shares outstanding, basic and diluted 48,361 36,488 33,419 See notes to the consolidated financial statements 65

CARDLYTICS, INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Amounts in thousands) Year Ended December 31, 2024 2023 2022 Net Loss $ (189,304) $ (134,702) $ (465,264) Other comprehensive loss: Foreign currency translation adjustments 1,134 (3,131) 5,112 Total Comprehensive Loss $ (188,170) $ (137,833) $ (460,152) See notes to the consolidated financial statements 66

CARDLYTICS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Amounts in thousands) Year Ended December 31, 2024: Additional Paid-In Capital Accumulated Other Comprehensive Income (loss) Accumulated Deficit Total Common Stock Shares Amount Balance – December 31, 2023 39,728 $ 9 $ 1,243,594 $ 2,467 $ (1,111,272) $ 134,798 Exercise of common stock options 6 — 15 — — 15 Stock-based compensation — — 45,370 — — 45,370 Issuance of restricted stock 3,503 1 — — — 1 Issuance of common stock, net of issuance cost 3,592 — 27,451 — — 27,451 Issuance of common stock, net of issuance costs - ATM Offering Program (as defined below) 3,908 — 48,151 — — 48,151 Issuance of common stock pursuant to the 2018 ESPP (as defined below) 520 — 2,262 — — 2,262 Termination of capped calls related to 2020 Convertible Senior Notes — — 115 — — 115 Other comprehensive income — — — 1,134 — 1,134 Net loss — — — — (189,304) (189,